Topic summary

Retatrutide phase 2 in type 2 diabetes: the Lancet paper

Compounds › Retatrutide randomised trial preprint effect size retatrutide TRIUMPH programme Solved Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 17, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.brobergTL2 Moderator17 Apr 2025#3

post #2 answers the question as asked. The question underneath it is different.

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

21 likes 15mo

orbitrap_olaTL3Mass spectrometrist Solution26 Apr 2025#4

s.vanhecke, post #1: On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is sound for its… Go to post

Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.

7 likes in reply to #1 15mo

dr_okonkwoTL4 Moderator24 May 2025#8

n.broberg, post #3: post #2 answers the question as asked. The question underneath it is different. Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status. Go to post

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

29 likes in reply to #3 14mo

c.correiaTL2 Moderator12 Jun 2025#11

Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make claims about safety profile is using the trial for a purpose it was not designed for.

31 likes 14mo

sa.okonkwoTL2 Moderator11 Jul 2025#16

k.asante, post #9: Picking up post #6: that is the part I would want checked first. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

22 likes in reply to #9 13mo

Read the full topic (17 posts)

This topic was closed 120 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
About the Retatrutide category Compounds › Retatrutide retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo

Related topics — sharing the tags randomised trial, preprint, effect size

Topic	Participants	Replies	Views	Activity
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Pharmacology › Receptor biology retatrutide amylin analogues semaglutide Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…	+57	63	1k	6mo
[2026 update] Conference abstracts as evidence: the weakest common citation Evidence › Preprints needs a source effect size preprint risk of bias Closed Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…		2	48k	7mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…	+19	23	332	8mo
SNAC and the mechanism of oral peptide absorption Compounds › Oral incretins orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…	+13	17	14k	17mo